SVRA News and Press, Savara Inc. From 02/15/24

2024-02-15 13:15:06 ET More on Savara Seeking Alpha’s Quant Rating on Savara Historical earnings data for Savara Financial information for Savara Read the full article on Seeking Alpha For further details see: JMP starts Savara at buy, cite...

Guggenheim 6th Annual Biotechnology Conference Oppenheimer 34th Annual Healthcare Life Sciences Conference Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participat...

The simple, no-cost, and noninvasive test is now available to physicians in the U.S. Company launches campaign in the U.S. to raise awareness of the rare autoimmune lung disease and need for early testing Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage bioph...

2023-12-20 08:17:04 ET More on Savara Seeking Alpha’s Quant Rating on Savara Historical earnings data for Savara Financial information for Savara For further details see: Savara added to Nasdaq Biotechnology Index

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023. The NASDAQ Biotechnology Index is d...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 at 1:00pm PT/4:00pm ET. A live we...

Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved 5.92% on the day to $3.67. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-...

2023-11-09 17:39:41 ET More on Savara Molgramostim: Savara's Single Shot At Success Seeking Alpha’s Quant Rating on Savara For further details see: Savara GAAP EPS of -$0.10

Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial Remains On-Track to Read Out by End of 2Q 2024 — 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinos...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...